Literature DB >> 2201451

TAR-independent activation of the HIV-1 LTR: evidence that tat requires specific regions of the promoter.

B Berkhout1, A Gatignol, A B Rabson, K T Jeang.   

Abstract

Replication of HIV-1 requires Tat, which stimulates gene expression through a target sequence, TAR. It is known that TAR is a Tat-responsive target. Since Tat increases transcriptional initiations from the HIV-1 LTR promoter, it is unclear mechanistically how Tat utilizes an RNA target. Here we show that TAR RNA is only one component of the Tat-responsive target. Efficient Tat trans-activation was observed only when TAR was present in conjunction with the HIV-1 LTR NF-kappa B/SP1 DNA sequences. TAR RNA outside of this context produced a suboptimal Tat response. We propose that TAR RNA serves an attachment function directing Tat to the LTR. A Tat protein engineered to interact with LTR DNA could trans-activate through a TAR-independent mechanism. This suggests that Tat also has a DNA target.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2201451     DOI: 10.1016/0092-8674(90)90120-4

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  109 in total

1.  Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR.

Authors:  F Demarchi; M I Gutierrez; M Giacca
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.

Authors:  C A Bohan; F Kashanchi; B Ensoli; L Buonaguro; K A Boris-Lawrie; J N Brady
Journal:  Gene Expr       Date:  1992

3.  Activation of expression of genes coding for extracellular matrix proteins in Tat-producing glioblastoma cells.

Authors:  J P Taylor; C Cupp; A Diaz; M Chowdhury; K Khalili; S A Jimenez; S Amini
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

4.  Functional comparison of the basic domains of the Tat proteins of human immunodeficiency virus types 1 and 2 in trans activation.

Authors:  B Elangovan; T Subramanian; G Chinnadurai
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

5.  Linker-scanning mutational analysis of the transcriptional activity of the human immunodeficiency virus type 1 long terminal repeat.

Authors:  S L Zeichner; J Y Kim; J C Alwine
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

6.  Cross-interaction between JC virus agnoprotein and human immunodeficiency virus type 1 (HIV-1) Tat modulates transcription of the HIV-1 long terminal repeat in glial cells.

Authors:  Dorota Kaniowska; Rafal Kaminski; Shohreh Amini; Sujatha Radhakrishnan; Jay Rappaport; Edward Johnson; Kamel Khalili; Luis Del Valle; Armine Darbinyan
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

7.  Novel biopanning strategy to identify epitopes associated with vaccine protection.

Authors:  Barbara C Bachler; Michael Humbert; Brisa Palikuqi; Nagadenahalli B Siddappa; Samir K Lakhashe; Robert A Rasmussen; Ruth M Ruprecht
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

8.  Release of human immunodeficiency virus by THP-1 cells and human macrophages is regulated by cellular adherence and activation.

Authors:  R J Shattock; J S Friedland; G E Griffin
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  Central nervous system-derived cells express a kappa B-binding activity that enhances human immunodeficiency virus type 1 transcription in vitro and facilitates TAR-independent transactivation by Tat.

Authors:  J P Taylor; R J Pomerantz; G V Raj; F Kashanchi; J N Brady; S Amini; K Khalili
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

10.  Transcriptional trans activation by human immunodeficiency virus type 1 Tat requires specific coactivators that are not basal factors.

Authors:  C Suñé; M A García-Blanco
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.